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Abstract We describe a case of Argininemia detected by
Michigan Newborn Screening (NBS). The Secretary’s
Advisory Committee on Heritable Disorders in Newborns
and Children recommends that every MS/MS newborn
screening program include Argininemia as part of their
uniform screening panel. While affected infants will be
detected by this testing, Arginine levels may take time to
accumulate. Thus, some infants may not be detected by this
methodology and early sample collection. In Michigan,
since initiating testing for Argininemia in 2006, there has
been workup of 23 cases for elevated Arginine identified by
NBS, with one case identified as affected. We report this
affected case. Subsequently, the Arginine/Ornithine ratio
was calculated for all cases and was found to be informa-
tive with respect to predicting whether a patient is affected
by Argininemia.
Introduction
The Secretary’s Advisory Committee on Heritable Disor-
ders in Newborns and Children recommends Arginemia be
included in the NBS uniform panel ( http://www.hrsa.gov/
advisorycommittees/mchbadvisory/heritabledisorders/
accessed September 11, 2012). Hyperarginemia (OMIM
207800) has an estimated incidence of one in 2 million
births (Scaglia and Lee 2006). Arginase is the enzyme
involved in the last step of the urea cycle and converts
L-arginine into L-ornithine and urea. The Arginase A1 gene
is located at 6 q23. Arginemia is an autosomal recessive
disorder. As opposed to other urea cycle defects, review of
the literature suggests that this condition does not classi-
cally present in the newborn period with symptoms of
hyperammonemia. Onset is typically between 2 and 4 years
of age. (Crombez and Cederbaum 2005)
One review of 55 patients with hyperarginemia indicated
that 52 of the patients were asymptomatic in early infancy
(De Dyn et al. 1997). If untreated however, these
individuals go on to develop symptoms of psychomotor
deterioration, loss of developmental milestones, and spas-
ticity. With appropriate adherence to dietary and medication
treatment, these symptoms may be prevented.
In some individuals it may take time for Arginine to
accumulate in the plasma, which may be in part due to the
presence of mitochondrial Arginase(Arginase II) which can
increase up to 40-fold if cystosolic Arginase I activity in
liver is deficient. There have been reports based on siblings
of known Argininemia patients that the Arginine level can
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be normal in the neonatal period in patients who will
ultimately be affected. Conversely, unaffected patients in
the newborn period may have Arginine levels above 150
umol/L and have normal Arginase activity.
Biochemical abnormalities include accumulation of
Arginine which is the hallmark of hyperargininemia.
Arginine can be measured by tandem mass spectrometry.
From a survey among participants of a LISTSERV for
metabolic specialists, while a number of cases have been
detected, at least one has been missed (Crombez and
Cederbaum 2005). Regarding this missed case in Califor-
nia, at that time the Arginine cutoff level was 200 umol/L,
and the infant’s Arginine level was under this level. The
cutoff has since been reduced to 50 umol/L and this patient
would have been identified (Cederbaum, June 21, 2012,
personal correspondence). However, lowering the cutoff
may contribute to more false positives being identified.
It would be helpful to have a test which could reduce
false positive results in screening for hyperargininemia, and
thus conserve resources by identifying which patients have
clinical elevations in Arginine. Such a test was suggested
by Currier: December 2010 Regional Collaborative Update.
Specifically a new ratio, Arg/Orn, was recommended
(Rinaldo 2010). This ratio was calculated for our Argini-
nemia case, the previous elevated False Positive cases, and
the normal population during the period of time since
Michigan has instituted MS/MS Newborn screening.
Case Report
We present a case of an infant with an elevated Arginine of
107 mmol/L (nml <68 mmol/L) with newborn screening of
dried bloodspot collection at 25 h. The Arginine/Ornithine
ratio was calculated to be 2.47 (Table 1). The infant was
born at 39 weeks to a G2P2 mother. Family history was
unremarkable for any consanguinity, and the patient was of
Dutch and Irish ancestry. Birth weight was 8 pounds and
birth length was 20.5 in. The postnatal course was
uncomplicated and the infant was discharged at 3 days of
age. The infant subsequently did well, feeding and growing
appropriately. However, a repeat NBS Arginine at day 19 of
life was 499 mmol/L (nml < 110 mmol/L) which prompted
further evaluation at the Children’s Hospital of Michigan.
In the ED, the ammonia level was initially 107mmol/L but
on repeat was 49 mmol/L. The patient’s plasma amino acids
showed an elevated Arginine level of 762 mmol /L (nml
40–148). The patient was subsequently started on a protein-
restricted diet of 2.2 g/kg which included Cyclinex
metabolic formula. The family was counseled regarding
Arginase deficiency, and given an emergency management
protocol outlining medical management in the event the
patient had symptoms of illness. Diagnosis was later
confirmed by DNA analysis which showed two mutations
in the Arginase gene; c.807–811 deletion (inherited from
the father), c.611A > G (p. D204G) (inherited from the
mother). Both of these are novel mutations and are
predicted to be deleterious, causing the disorder.
Results and Discussion
This was the first Argininemia case identified by the
Michigan NBS Program since initiating testing for Arginine
in 2006 (>675,000 samples tested). Twenty-three cases
with elevated Arginine (not due to TPN feeding) had been
identified. For these 23 cases, 22 had confirmatory testing
accomplished by a repeat Arginine level, which were all
within normal limits. Our case highlights the challenge of
identifying a patient with Argininemia, and how best to
confirm clinical suspicion of a patient with an elevated
Arginine value.
The December 2010 Regional Collaborative Update
presented a new ratio: Arginine/Ornithine proposed by
Bob Currier (Rinaldo 2010). This prompted the MI NBS
laboratory to calculate the Arg/Orn ratio for this Arginine-
mia case, the previous presumptive positive cases, and the
normal population.
The initial Arginine/Ornithine ratio was 2.47 for our case
as measured at 25 h of age (Table 1). For the period
2006–2012, for patients not on TPN or hospitalized in the
NICU, the mean Arginine value was 11.8, median value
was 10.6 (SD ¼ 6.12, 99 % ¼ 31.90). The mean Arginine/
Ornithine ratio for this time period was 0.14, the median
Table 1 Arginine results with calculated Arginine/Ornithine ratio for
patients identified as having elevated Arginine level by Michigan







25 107 43 2.47
36 68 94 0.72
0 75 106 0.71
6 83 120 0.69
26 77 121 0.64
24 76 123 0.62
34 75 125 0.60
26 75 144 0.52
27 76 164 0.46
25 71 187 0.38
25 70 192 0.37
24 71 193 0.37
168 74 219 0.34
36 79 279 0.28
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was 0.12 (SD 0.07, 99 % ¼ 0.35). At present, the Michigan
NBS Program has set the cutoff for Arginine/Ornithine ratio
at 0.8 and is in the process of validating this ratio. To
further illustrate the utility of this ratio, Fig. 1 represents the
Arginine values for over 40,000 infants from one hospital
in Michigan, plus the false-positive cases and this Argini-
nemia case. For a number of infants, Arginine values were
above the designated cutoff. Figure 2 represents the
Arginine/Ornithine ratios for over 40,000 infants from one
hospital in Michigan, plus the false positive cases and this
Argininemia case. Only the infant that was a true-positive
case for Argininemia had an Arg/Orn above 0.8.
Fig. 1 Arginine Levels (umol/L) for newborn screening cases from one hospital in Michigan from 2006 to 2012 plus the MI false-positive cases
and this Argininemia case. Arginine cutoff (c/o) ¼ 68. FP ¼ False positives, TP ¼True positives
Fig. 2 Arginine/Ornithine ratios for newborn screening cases from one hospital in Michigan from 2006 to 2012 plus the MI false-positive cases
and this Argininemia case, c/o ¼ 0.80. TP ¼ True positive
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This emphasizes the utility of the Arg/Orn ratio when
screening for Argininemia patients.
Utilizing this ratio should both reduce the false positive rate
for Argininemia and allow the Arginine cutoff to be lowered.
It can serve as a tool to improve selectivity and sensitivity for
detecting patients with this condition. In addition, if this ratio
is not available to the clinician, this case illustrates the
importance of repeat testing in the event of an elevated
Arginine value above the cutoff. Plasma Arginine may be on
an upward trend, as was the case with our patient.
Take-Home Message
The Arginine/Ornithine ratio may be an important tool in
predicting which patients are affected by Argininemia.
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